Literature DB >> 2196303

Resistance and allergy to recombinant human insulin.

M A Ganz1, T Unterman, M Roberts, R Uy, S Sahgal, M Samter, L C Grammer.   

Abstract

Insulin allergy and antibody-mediated resistance may complicate therapy with animal insulins. We describe a 53-year-old man manifesting both resistance and persistent systemic allergy despite treatment with recombinant human insulin. Insulin resistance and symptoms of allergy appeared in this patient several months after initiating therapy with mixed beef-pork insulin, as is often the case. Symptoms initially improved, but persisted, and then worsened again, despite continuous human insulin therapy. Total insulin-binding capacity by Scatchard analysis, high plasma insulin-binding capacity, and specific anti-insulin antibody levels were consistent with an immunologic form of insulin resistance. Glucocorticoid therapy was required both to reduce allergic findings and to restore glycemic control. Although recently available human insulins may be less immunogenic than animal forms, immune responses to exogenous human insulin still may pose significant clinical problems.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2196303     DOI: 10.1016/s0091-6749(05)80122-8

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  3 in total

1.  Can a faulty injection technique lead to a localized insulin allergy?

Authors:  Trinanjan Sanyal; Sujoy Ghosh; Subhankar Chowdhury; Satinath Mukherjee
Journal:  Indian J Endocrinol Metab       Date:  2013-10

Review 2.  Exogenous insulin antibody syndrome (EIAS): a clinical syndrome associated with insulin antibodies induced by exogenous insulin in diabetic patients.

Authors:  Xiaolei Hu; Fengling Chen
Journal:  Endocr Connect       Date:  2017-12-12       Impact factor: 3.335

3.  Insulin signaling pathways in a patient with insulin resistance of difficult management - a case report.

Authors:  Giselle F Taboada; Marta S de Freitas; Fernanda H da S Corrêa; Carlos Rma Junior; Marília de B Gomes
Journal:  Diabetol Metab Syndr       Date:  2009-11-26       Impact factor: 3.320

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.